The Clinical Trial Award, offered through the U.S. DoD CDMRP under the FY26 Ovarian Cancer Research Program, funds ovarian cancer clinical trials with strong potential for near-term impact on patient care. It is the trial-focused counterpart to the program’s basic and translational mechanisms, supporting investigators who lead trial-capable teams. The program announcement (HT942526OCRPCTA) was released May 4, 2026, with applications submitted through eBRAP.
Eligibility Criteria:
- Open to independent investigators leading trial-capable teams.
- U.S. and international institutions are generally eligible under CDMRP application instructions.
- Trial readiness and team requirements are detailed in the Program Announcement and should be confirmed before applying.
Funding Details:
- Award amounts and period of performance are specified in the FY26 OCRP Program Announcement (HT942526OCRPCTA); confirm current figures via eBRAP before applying.
Deadline:
- Letter of Intent due: September 15, 2026 (5:00 p.m. ET).
- Full application due: October 1, 2026 (11:59 p.m. ET).
- Program announcement released: May 4, 2026.
Where to Go for Further Information:
- DoD Ovarian Cancer Research Program (Program Announcement HT942526OCRPCTA).
- Letter of Intent and full application submitted via eBRAP.